Document is current

Article History

Received: 6 April 2025

Accepted: 21 July 2025

First Online: 12 August 2025

Declarations

:

: The authors declare the following financial interests/personal relationships, which may be considered potential competing interests: Mª Carmen Areses has received honoraria for educational activities or advisory roles from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Merck, MSD, Novartis, Pfizer, PierreFabre, Roche, Sanofi, and Takeda, and has received travel accommodations and expenses from AstraZeneca, Bristol-Myers Squibb, MSD, Roche, Sanofi, and Takeda. Luis León-Mateos has received consulting fees from AstraZeneca, Bristol-Myers Squib, Merck, MSD, Roche, Sanofi, and Takeda; has received payment or honoraria for lectures, presentations, manuscript writing, and participation in speakers’ bureaus and educational events from AstraZeneca, Bristol-Myers Squib, Jansen, Merck, MSD, Novartis, Pfizer, Roche, Sanofi, and Takeda; and has received support for attending meetings and/or travel accommodations from AstraZeneca, Bristol-Myers Squib, Jansen, MSD, Pfizer, Roche, Sanofi, and Takeda. Sofia Silva-Diaz received speaker honoraria from LEO Pharma. Ana Alonso received speaker honoraria from Roche, and Bristol-Myers Squibb. Martin Lázaro-Quintela has received advisory board member fees from Ipsen, Bristol-Myers Squibb, Bayer, Merck, Beigene, and Novartis; speaker honoraria from Amgen, Roche, Astra-Zeneca, Lilly, Bristol-Myers Squibb, MSD, Ipsen, and Janssen; and travel grants from Ipsen, Roche, MSD, and Bristol-Myers Squibb. Natalia Fernández Nuñez received speaker-honoraria from AstraZeneca. Francisco Javier Afonso Afonso has received consultant and/or speaking and/or advisory roles from AstraZeneca, Pfizer, Bristol-Myers Squib, MSD, Roche, Ipsen, Sanofi, Novartis, and Boehringer, and has received grants or travel support from MSD, Pfizer, Sanofi, Bristol-Myers Squib, Takeda, and Roche. Pablo Freijido-Álvarez declares no conflicts of interest. Manuel Fernández-Bruno declares no conflicts of interest. Soledad Cameselle-García has received speaker honoraria from Amgen, Rovi, and Pfizer, and has received support for attending meetings and/or travel grants from AstraZeneca, Bristol-Myers Squib, MSD, Roche, and Rovi. Clara González-Ojea declares no conflicts of interest. Gerardo Huidobro declares no conflicts of interest. Blanca Távara Silva declares no conflicts of interest. Carme García-Lorenzo declares no conflicts of interest. Javier Álvarez declares no conflicts of interest. Patricia Cordeiro González declare that they have no conflicts of interest. Jesús García Mata was also awarded. Cristina Azpitarte-Raposeiras has received speaker honoraria from Bristol-Myers Squib, Merck, Takeda, Janssen, AstraZeneca, Roche, Lilly, Bayer, MSD, and Ipsen, and has received travel grants from Roche, MSD, Lilly, Ipsen, AstraZeneca, Takeda, Bayer, and Merck. Luis Ruiz de Almirón Lomo has received consulting fees and honoraria for educational events from AstraZeneca, Bristol-Myers Squib, Merck, Novartis, Pierre-Fabre, Roche, Lilly, and Pfizer and has received support for attending meetings and/or travel grants from Pfizer, AstraZeneca, Roche, Sanofi, Gilead, and Novartis. Víctor Cebey-López declare that they have no conflicts of interest. Joaquín Mosquera Martínez declares no conflicts of interest. Jorge García-González has received consulting fees and honoraria for educational events from AstraZeneca, Bristol-Myers Squib, Jansen, Merck, Novartis, Pierre-Fabre, Roche, Sanofi, and Takeda and has received support for attending meetings and/or travel grants from AstraZeneca, Bristol-Myers Squib, Jansen, MSD, Roche, Rovi, Sanofi, and Takeda. Lucía Santomé has received advisory board member fees from Pfizer, and travel and/or education grants from AstraZeneca, Bristol-Myers Squibb, Hoffmann-La Roche, Merck Serono, Bayer, Ipse, Janssen, and Astellas. Margarita Amenedo has received honoraria for presentations and participation in speakers'bureaus from AstraZeneca, MSD, and Pharmamar, and has received support for attending meetings from GSK, Lilly, and AstraZeneca. José Luis Fírvida-Pérez received advisory board member fees from BeiGene, Boehringer, Sanofi, and Takeda, and speaker honoraria from Astra, Bristol-Myers Squib, Boehringer, Lilly, MSD, Pfizer, Roche, and Takeda.

: This study was reviewed and approved by the Local Research Ethics Committee of the Autonomous Community of Galicia (Spain).

: Written informed consent was obtained from all the participants before enrollment in the study.